# **DEXCOM INC.**

ISIN: US2521311074 WKN: 252131107 Asset Class: Stock



#### **Company Profile**

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

# Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,425,900,000		3,668,800,000		3,684,400,000	
Common stock capital		400,000		400,000		100,000
Fixed assets	1,838,600,000		1,722,900,000		1,179,200,000	
Equity capital of a company		2,068,600,000		2,131,800,000		2,251,500,000
Cash and cash equivalents	566,300,000		642,300,000		1,052,600,000	
Accrued liabilities		15,700,000		0		0
Other assets	-		-		-	
Current liabilities		1,556,000,000		1,839,300,000		727,100,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		2,639,900,000		1,420,600,000		1,885,000,000
Different income		-		-		-
Other liabilities		12,600,000		31,100,000		27,100,000
Total assets	6,264,500,000	6,264,500,000	5,391,700,000	5,391,700,000	4,863,600,000	4,863,600,000

# **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	9,600	7,600	6,300
Equity ratio	33.02%	39.54%	46.29%
Debt-equity ratio	202.84%	152.92%	116.02%

	41		
	ч	nn	T C
v	ч	ш	11

	2023	2022	2021
Tour Europea Bota			
Tax Expense Rate	23.78%	12.69%	11.04%

# **DEXCOM INC.**

ISIN: US2521311074 WKN: 252131107 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	3,622,300,000	2,909,800,000	2,448,500,000
Net income	541,500,000	341,200,000	154,700,000
EBIT	556,741,220	382,625,240	256,267,320
Operating income before taxes	710,400,000	390,800,000	173,900,000
Cash Flow	748,500,000	669,500,000	442,500,000
Net interest income	114,700,000	-18,600,000	-100,300,000
Research and development expenses	497,700,000	484,200,000	604,200,000
Income taxes	168,900,000	49,600,000	19,200,000
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	352,646	357,829	363,233

# **Board of Directors**

Members of Management Board		
Barbara Kahn	Member of Board of Directors	
Eric Topol	Member of Board of Directors	
Bridgette Heller	Member of Board of Directors	
Karen Dahut	Member of Board of Directors	
Kyle Malady	Member of Board of Directors	
Mark Foletta	Member of Board of Directors	
Nicholas Augustinos	Member of Board of Directors	
Richard Collins	Member of Board of Directors	
Rimma Driscoll	Member of Board of Directors	
Steven Altman	Member of Board of Directors	
Kevin Sayer	Chairman of Managing Board	
Barry Regan	Member of Executive Committee	
Donald Abbey	Member of Executive Committee	
Girish Naganathan	Member of Executive Committee	
Jake Leach	Member of Executive Committee	
Jereme Sylvain	Member of Executive Committee	
Matthew Dolan	Member of Executive Committee	
Michael Brown	Member of Executive Committee	
Paul Flynn	Member of Executive Committee	
Sadie Stern	Member of Executive Committee	
Shelly Selvaraj	Member of Executive Committee	
Steven Pacelli	Member of Executive Committee	
Teri Lawver	Member of Executive Committee	